Assessment of basic indirect pharmacodynamic response models with physiological limits

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 33, Issue 2, 2006, Pages 167-193

  Yao, Zhenling ^a   Krzyzanski, Wojciech ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Indirect response models; Pharmacodynamics; Physiological limits

Indexed keywords

ANALYTICAL PARAMETERS; ARTICLE; BASIC INDIRECT PHARMACODYNAMIC RESPONSE MODEL; KINETICS; MATHEMATICAL MODEL; PRIORITY JOURNAL; RESPONSE TIME; SIMULATION;

ADULT; ALDEHYDE REDUCTASE; ALGORITHMS; ENZYME INHIBITORS; ERYTHROCYTES; HOMEOSTASIS; HUMANS; INDOLIZINES; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NAPHTHALENES; PHARMACEUTICAL PREPARATIONS; SORBITOL; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 33645806750     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-006-9003-7     Document Type: Article

References (19)

1. N. L. Dayneka, V. Garg, and W. J. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21:457-478 (1993).
2. W. J. Jusko and H. C. Ko. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56:406-419 (1994).
3. R. Ramakrishnan, D. C. DuBois, R. R. Almon, N. A. Pyszczynski, and W. J. Jusko. Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J. Pharmacokinet. Pharmacodyn. 29:1-24 (2002).
4. A. Sharma, W. F. Ebling, and W. J. Jusko. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J. Pharm. Sci. 87:1577-1584 (1998).
5. W. Krzyzanski, R. Ramakrishnan, and W. J. Jusko. Basic pharmacodynamic models for agents that alter production of natural cells. J. Pharmacokinet. Biopharm. 27:467-489 (1999).
6. A. Chakraborty, W. Krzyzanski, and W. J. Jusko. Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. J. Pharmacokinet. Biopharm. 27:23-43 (1999).
7. W. Krzyzanski. Asymptotics of the total net direct pharmacological effect for large drug doses. J. Math. Biol. 41:477-492 (2000).
8. W. Krzyzanski and W. J. Jusko. Application of moment analysis to the sigmoid effect model for drug administered intravenously. Pharm. Res. 14:949-952 (1997).
9. W. Krzyzanski and W. J. Jusko. Integrated functions for four basic models of indirect pharmacodynamic response. J. Pharm. Sci. 87:67-72 (1998).
10. A. Sharma and W. J. Jusko. Characterization of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 24:611-635 (1996).
11. D. Z. D'Argenio and A. Schumitzky. ADAPT II User's Guide: Pharmacokinetic/pharmacodynamic Systems Analysis Software, Biomedical Simulations Resource, Los Angeles, 1997.
12. T. Fujita, Y. Matsumoto, T. Kimura, S. Yokota, M. Sawada, M. Majima, Y. Ohtani, and Y. Kumagai. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br. J. Clin. Pharmacol. 54:283-294 (2002).
13. D. Drafta, A. E. Schindler, E. Stroe, and E. Neacsu. Age-related changes of plasma steroids in normal adult males. J. Steroid. Biochem. 17:683-687 (1982).
14. J. M. van Griensven, W. J. Jusko, H. H. Lemkes, R. Kroon, C. J. Verhorst, S. T. Chiang, and A. F. Cohen. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. Clin. Pharmacol. Ther. 58:631-640 (1995).
15. J. Schulkin. Rethinking Homeostasis: Allostatic Regulation in Physiology and Pathophysiology, The MIT Press, London, 2003.
16. K. Kurokawa. How is plasma calcium held constant? Milieu interieur of calcium. Kidney Int. 49:1760-1764 (1996).
17. T. B. Robertson. The Chemical Basis of Growth and Senescence. J. B. Lippincott, Philadelphia and London, 1923.
18. J. A. Bauer and H. L. Fung. Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm. Res. 11:816-823 (1994).
19. M. Gardmark, L. Brynne, M. Hammarlund-Udenaes, and M. O. Karlsson. Interchangeability and predictive performance of empirical tolerance models. Clin. Pharmacokinet. 36:145-167 (1999).